spacer
home > pmps > spring 2007 > readability testing – a bitter ‘pil’ to swallow?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Readability Testing – A Bitter ‘Pil’ to Swallow?

Sophie Hobson at TRAC Services examines the processes fundamental to adapting patient information leaflets (PIL) in time for the July 2008 deadline

With less than 14 months before all patient information leaflets (PIL) in the UK have to comply with mandatory readability requirements, as set out in Article 59(3) of Directive 2004/27/EC, the question of whether pharmaceutical manufacturers are on target to meet the deadline is one that is being asked more frequently.

For those pharmaceutical manufacturers that have yet to start the process or that are in the early stages of testing their patient information leaflets, the clock is ticking a lot faster than they may think. This feature looks at the processes that pharmaceutical companies need to be going through if they are to meet the July 1st, 2008 deadline. Surveys have revealed that people in the UK want more medicines information than they currently get (1), and that they value the PIL more highly than any source, other than doctors and pharmacists (2). But in the past, the vast majority of PILs, whilst factually correct, did not present the information in a way that the patient could easily understand. European Law currently states:

“The package leaflet shall reflect the results of the consultations with the target patient groups to ensure that it is legible, clear and easy to use (3). The results of assessments carried out in cooperation with target patient groups shall also be provided to the competent authority (4)”.

Whilst improving PILs is something we are all now committed to, actually achieving this goal (and the cost of doing so) is something that is falling at the feet of those involved in the manufacture and marketing of pharmaceutical products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After graduating from the University of London, Sophie Hobson earned a place on a graduate scheme working in a regulatory consultancy. Having joined TRAC Services, she developed her knowledge and experience to create a readability and user testing service for the company to provide to its clients. As a result of this work Sophie researched, designed and developed a testing programme which was launched earlier this year and which she now manages full time.
spacer
Sophie Hobson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Safe’n’Spray™, the smart electronic concept device with child-resistant and locking features, wins the ‘Best Innovation In Drug Delivery Device’ Award at Pharmapack 2020

On February 5th, during the Pharmapack Awards Ceremony, Safe’n’Spray, Nemera’s smart electronic concept device with child-resistant and locking features, was celebrated as the “Best Innovation in Drug Delivery Device”.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement